Pegvisomant and current approaches to the medical treatment of acromegaly (literature review and case report)
This review provides the main results of clinical trials and the literature on the experience of using pegvisomant, the first drug from the class of growth hormone receptor antagonists. The mechanism of action of the drug, its effectiveness with respect to disease control and its effect on complicat...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2019-12-01
|
| Series: | Ожирение и метаболизм |
| Subjects: | |
| Online Access: | https://www.omet-endojournals.ru/jour/article/view/12207 |
| _version_ | 1797204636051963904 |
|---|---|
| author | Larisa K. Dzeranova Alexandra A. Povaliaeva Anastasia A. Romanova Elena G. Przhiyalkovskaya Ekaterina A. Pigarova Natalia S. Fedorova |
| author_facet | Larisa K. Dzeranova Alexandra A. Povaliaeva Anastasia A. Romanova Elena G. Przhiyalkovskaya Ekaterina A. Pigarova Natalia S. Fedorova |
| author_sort | Larisa K. Dzeranova |
| collection | DOAJ |
| description | This review provides the main results of clinical trials and the literature on the experience of using pegvisomant, the first drug from the class of growth hormone receptor antagonists. The mechanism of action of the drug, its effectiveness with respect to disease control and its effect on complications, information on adverse events, and brief information on the experience of use during pregnancy are discussed in detail. In conclusion, a clinical observation of successful use of pegvisomant in resistant to standart treatment acromegaly is given. A discussion of the available literature data, the results of clinical studies and practical experience allows us to conclude that the drug is highly effective in terms of achieving biochemical remission of acromegaly, and also has a number of additional valuable properties: it is capable of improvement of patients’ glucose metabolism and quality of life and has a minimal amount of adverse events. Pegvisomant is currently registered in the Russian Federation only for use in monotherapy; the possibility of combination therapy with somatostatin analogues will additionally allow to reliably control the growth of the pituitary adenoma and significantly cut treatment costs by reducing the dose of pegvisomant. These features of the drug make it very relevant when discussing issues related to drug therapy of acromegaly, and suggest a good prospect for use in clinical practice. |
| first_indexed | 2024-03-08T09:13:42Z |
| format | Article |
| id | doaj.art-dcc48982f762438cb7b2f0e9b535d8cb |
| institution | Directory Open Access Journal |
| issn | 2071-8713 2306-5524 |
| language | English |
| last_indexed | 2024-04-24T08:38:22Z |
| publishDate | 2019-12-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Ожирение и метаболизм |
| spelling | doaj.art-dcc48982f762438cb7b2f0e9b535d8cb2024-04-16T16:16:12ZengEndocrinology Research CentreОжирение и метаболизм2071-87132306-55242019-12-01164737910.14341/omet1220710567Pegvisomant and current approaches to the medical treatment of acromegaly (literature review and case report)Larisa K. Dzeranova0Alexandra A. Povaliaeva1Anastasia A. Romanova2Elena G. Przhiyalkovskaya3Ekaterina A. Pigarova4Natalia S. Fedorova5Endocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreThis review provides the main results of clinical trials and the literature on the experience of using pegvisomant, the first drug from the class of growth hormone receptor antagonists. The mechanism of action of the drug, its effectiveness with respect to disease control and its effect on complications, information on adverse events, and brief information on the experience of use during pregnancy are discussed in detail. In conclusion, a clinical observation of successful use of pegvisomant in resistant to standart treatment acromegaly is given. A discussion of the available literature data, the results of clinical studies and practical experience allows us to conclude that the drug is highly effective in terms of achieving biochemical remission of acromegaly, and also has a number of additional valuable properties: it is capable of improvement of patients’ glucose metabolism and quality of life and has a minimal amount of adverse events. Pegvisomant is currently registered in the Russian Federation only for use in monotherapy; the possibility of combination therapy with somatostatin analogues will additionally allow to reliably control the growth of the pituitary adenoma and significantly cut treatment costs by reducing the dose of pegvisomant. These features of the drug make it very relevant when discussing issues related to drug therapy of acromegaly, and suggest a good prospect for use in clinical practice.https://www.omet-endojournals.ru/jour/article/view/12207acromegalygrowth hormonepegvisomantsomavert |
| spellingShingle | Larisa K. Dzeranova Alexandra A. Povaliaeva Anastasia A. Romanova Elena G. Przhiyalkovskaya Ekaterina A. Pigarova Natalia S. Fedorova Pegvisomant and current approaches to the medical treatment of acromegaly (literature review and case report) Ожирение и метаболизм acromegaly growth hormone pegvisomant somavert |
| title | Pegvisomant and current approaches to the medical treatment of acromegaly (literature review and case report) |
| title_full | Pegvisomant and current approaches to the medical treatment of acromegaly (literature review and case report) |
| title_fullStr | Pegvisomant and current approaches to the medical treatment of acromegaly (literature review and case report) |
| title_full_unstemmed | Pegvisomant and current approaches to the medical treatment of acromegaly (literature review and case report) |
| title_short | Pegvisomant and current approaches to the medical treatment of acromegaly (literature review and case report) |
| title_sort | pegvisomant and current approaches to the medical treatment of acromegaly literature review and case report |
| topic | acromegaly growth hormone pegvisomant somavert |
| url | https://www.omet-endojournals.ru/jour/article/view/12207 |
| work_keys_str_mv | AT larisakdzeranova pegvisomantandcurrentapproachestothemedicaltreatmentofacromegalyliteraturereviewandcasereport AT alexandraapovaliaeva pegvisomantandcurrentapproachestothemedicaltreatmentofacromegalyliteraturereviewandcasereport AT anastasiaaromanova pegvisomantandcurrentapproachestothemedicaltreatmentofacromegalyliteraturereviewandcasereport AT elenagprzhiyalkovskaya pegvisomantandcurrentapproachestothemedicaltreatmentofacromegalyliteraturereviewandcasereport AT ekaterinaapigarova pegvisomantandcurrentapproachestothemedicaltreatmentofacromegalyliteraturereviewandcasereport AT nataliasfedorova pegvisomantandcurrentapproachestothemedicaltreatmentofacromegalyliteraturereviewandcasereport |